FOLD

Amicus Therapeutics Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↑ 8/10
  • Value↓ 1/10
Amicus Therapeutics sales and earnings growth
FOLD Growth
Good
  • Revenue Y/Y↑ 20.05%
  • EPS Y/Y↑ 50.00%
  • FCF Y/Y↑ 179.72%
Amicus Therapeutics gross and profit margin trends
FOLD Profitability
Neutral
  • Gross margin ↑ 88.50%
  • EPS margin↓ -4.30%
  • ROIC 5Y↓ -7.44%
Amicus Therapeutics net debt vs free cash flow
FOLD Risk
Good
  • Debt / Equity↓ 1.6
  • Debt / FCF↑ 7.7
  • Interest coverage↓ 1.0

Amicus Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Good risk rating.

More Biotechnology stocks ↗